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Abstract
Pulmonary arterial hypertension (PAH) is a rapidly degenerating and devastating disease of 
increased pulmonary vessel resistance leading to right heart failure. Palliative modalities remain 
limited despite recent endeavors to investigate the mechanisms underlying increased pulmonary 
vascular resistance (PVR), i.e. aberrant vascular remodeling and occlusion. However, little is 
known of the molecular mechanisms responsible for endothelial proliferation, a root cause of 
PAH-associated vascular remodeling. Lung tissue specimens from PAH and non-PAH patients and 
hypoxia-exposed human pulmonary artery endothelial cells (ECs) (HPAEC) were assessed for 
mRNA and protein expression. Reactive oxygen species (ROS) were measured using cytochrome c 
and Amplex Red assays. Findings demonstrate for the first time an up-regulation of NADPH 
oxidase 1 (Nox1) at the transcript and protein level in resistance vessels from PAH compared with 
non-PAH patients. This coincided with an increase in ROS production and expression of bone 
morphogenetic protein (BMP) antagonist Gremlin1 (Grem1). In HPAEC, hypoxia induced Nox1 
subunit expression, assembly, and oxidase activity leading to elevation in sonic hedgehog (SHH) 
and Grem1 expression. Nox1 gene silencing abrogated this cascade. Moreover, loss of either 
Nox1, SHH or Grem1 attenuated hypoxia-induced EC proliferation. Together, these data support a 
Nox1-SHH-Grem1 signaling axis in pulmonary vascular endothelium that is likely to contribute to 
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pathophysiological endothelial proliferation and the progression of PAH. These findings also 
support targeting of Nox1 as a viable therapeutic option to combat PAH.
Introduction
Despite the availability of a number of FDA-approved drugs, pulmonary arterial 
hypertension (PAH) remains a deadly disease with a median survival of 2.8 years from 
diagnosis [1,2]. Current therapies focus on dilation of the pulmonary vasculature in an 
attempt to attenuate pulmonary vascular resistance (PVR) and reduce right ventricle (RV) 
pressure overload which ultimately leads to right heart maladaptive hypertrophy and failure 
[3,4], the major cause of death in PAH [2]. However, currently there are no effective drugs 
that reverse the extensive vascular remodeling responsible for subsequent elevation of PVR. 
Endothelial dysfunction and proliferation are at the root of vascular remodeling in PAH [4–
8], being associated with increased plexiform lesion (PL) formation and vascular occlusion 
[3,5]. Insight into the pathways governing endothelial proliferation in PAH remains scarce 
and, to date, no effective strategies exist which target increased endothelial cell (EC) 
proliferation in PAH.
Reactive oxygen species (ROS) and more recently NADPH oxidase (Nox) enzymes, have 
been implicated in the pathogenesis of PAH [9,10]. Nonetheless, this literature is 
surprisingly sparse and the role of Nox proteins in pulmonary EC proliferation is not known. 
Indeed, despite evidence supporting a role for the NADPH oxidase 1 (Nox1) isoform in 
systemic vascular proliferation and remodeling [11], little is known about the function for 
Nox1 in the pulmonary endothelium and PAH.
An in silico interactome suggested a potential link between Nox and the endogenous bone 
morphogenetic protein (BMP) antagonist Gremlin1 (Grem1) [12–15]. Grem1 is a 28-kDa 
member of the Differential screening-selected gene Aberrative in Neuroblastoma (DAN) 
family of glycoproteins [12] and functions as an antagonist of BMP2 and BMP4 signaling 
[12,13,15,16]. BMP4 signaling is associated with the maintenance of endothelial 
homeostasis, repair, and abated proliferation [14,17,18]. Thus, we postulated that EC Nox 
up-regulates Grem1 and leads to hyperproliferation in PAH. Indeed, the mechanisms by 
which Grem1 expression and secretion are regulated by Nox and ROS in PAH are entirely 
unknown.
The current study addresses a gap in knowledge of the mechanisms underlying endothelial 
proliferation in PAH. We report for the first time that Grem1 relaysNox1-mediated EC 
proliferation in an in vitro model of PAH, and draw strong preclinical and translational links 
amongst ROS, Nox1, and Grem1. Our data also identify sonic hedgehog (SHH), a pro-
angiogenic factor [19], as an intermediary between Nox1 and Grem1 in EC.
Materials and methods
Materials and reagents
Cytochrome c, superoxide dismutase (SOD), catalase, diphenylene iodonium (DPI) chloride, 
PMSF, and dihydroethidium (DHE) were purchased from Sigma–Aldrich (St. Louis, MO, 
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U.S.A.). Amplex Red and propidium iodide were purchased from Life Technologies (Grand 
Island, NY, U.S.A.). Protease and phosphatase inhibitor cocktail tablets were purchased 
from Roche Diagnostics GmbH (Mannheim, Germany). Reagents and primers for qPCR 
were purchased from Life Technologies. Antibodies for Grem1, Nox1, p47phox, and β-actin 
were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, U.S.A.), and Nox 
organizer 1 (NoxO1) antibody was purchased from Rockland Immunochemicals. Nox 
activator 1 (NoxA1), SHH and BrdU antibodies were purchased from Abcam, (Cambridge, 
MA, U.S.A.). Carboxyfluorescein succinimidyl ester (CFSE) CellTrace™ Cell Proliferation 
Kit was purchased from Life Technologies.
Human tissue samples
Human tissue sample collection and processing were approved by the Institutional Review 
Board of the University of Pittsburgh. Lung tissue samples from PAH and non-PAH controls 
were obtained from human subjects who had given written consents. Tissues were collected 
either from recipient lungs during transplant surgery or during warm autopsy organ 
collection. Samples were de-identified with researchers performing the biochemical assays 
blinded to patient information. Samples were homogenized in ice-cold HBSS containing 
protease inhibitor cocktail tablets supplemented with PMSF using mortar and pestle and 
centrifuged at 1000×g to prepare homogenates from tissue samples. Protein concentrations 
were measured and samples were either processed for ROS measurement or Western blot 
analysis for protein expression. Demographic data of the non-PAH and PAH patient samples 
are provided in Table 1.
Sugen 5416/hypoxia rat model
All animal experiments were approved by the University of Pittsburgh Animal Care and Use 
Committee. To induce PAH, the SU5416 (Sugen)/hypoxia model was employed as 
previously described [20–22] with modifications. Female rats (7–10 per group; 250–275 g; 
Charles River Laboratories, Cambridge, MA) were injected with a single subcutaneous 
bolus of SU5416 (100 mg/kg, Sigma, St. Louis, MO) and subsequently subjected to hypoxia 
(10% O2) for 3 weeks, followed by 1 week of normoxia (21% O2). For ROS measurements, 
tissues were processed as detailed for human samples above.
Cell culture and treatment
Human pulmonary artery ECs (HPAEC; Lonza, Walkersville, MD, U.S.A.) were grown in 
EBM-2 medium containing EGM-2 bullet kit components (Lonza, Walkersville, MD, 
U.S.A.). Cells were seeded the day before experimentation and synchronized in serum-
reduced medium (0.2% FBS) for 16 h prior to further experimentation. Cells between 
passages 3 and 6 were used in all the experiments. Hypoxic treatment in vitro was used to 
most closely resemble the in vivo disease as previously described [23–25]. Cells were 
incubated in either normoxia (21% oxygen) or hypoxia (1% oxygen) for 6, 12, 24, 36, or 48 
h and subjected to either homogenization in ice-cold disruption buffer (HBSS containing 1.8 
mM CaCl2, 0.8 mM MgCl2, and 0.1 mM protease inhibitor PMSF) or trypsinized for intact 
cell analysis. To gene silence Grem1, SHH, and Nox1, HPAEC were seeded at a density to 
achieve an overnight 75–80% confluence followed by transfection with Grem1, SHH, or 
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Nox1 siRNA or their scrambled control siRNA (Life Technologies) using the Lipofectamine 
2000 transfection reagent (Life Technologies) according to the manufacturer’s protocol as 
documented previously [26]. Gene silencing was confirmed using immunoblotting (detailed 
below) and knockdown expressed as a percent of siRNA-scrambled controls.
Quantitative real-time RT-PCR
Expression of mRNA was quantitated as previously described [26]. Briefly, total RNAs were 
extracted from human lung tissues and from HPAEC using the RNeasy Plus Mini Kit 
(Qiagen). Total RNA (1–2 µg) was reverse transcribed to cDNA using SuperscriptIII reverse 
transcriptase (Life Technologies) following the manufacturer’s protocol. Taqman probe and 
Universal PCR Master Mix and Nox1, Grem1, p47phox, NoxO1, NoxA1 or 18S primers 
(Life Technologies) were used for qPCR in a 7900HT Fast Real-Time PCR System (Life 
Technologies) according to the manufacturer’s protocol for 40 cycles. Relative quantitation 
to corresponding control was obtained using the threshold cycle (Ct) method with 18S as the 
housekeeping gene and relative expression calculated as 2−ΔΔCt.
Western blot
Western blot experiments were performed as described previously [27,28]. Total protein 
(100 or 30 µg) from tissue homogenates or cell lysates, respectively, were added to Tris-
glycine SDS sample buffer, boiled, resolved with SDS/PAGE, and transferred onto Trans-
Blot nitrocellulose membranes (Bio–Rad). Membranes were blocked with the Odyssey 
Blocking Buffer (LI-COR Biosciences, Lincoln, NE) and incubated with rabbit anti-p47phox 
(1:500 dilution, Santa Cruz Biotechnology), rabbit anti-Grem1 (1:250, Santa Cruz 
Biotechnology), goat anti-Nox1 (1:500, Santa Cruz Biotechnology), rabbit anti-NoxO1 
(1:1000, Rockland Immunochemicals), rabbit anti-NoxA1 (1:1000, Abcam), mouse anti-
SHH (1:1000, Abcam) or mouse anti-β-actin (1:2000, Santa Cruz Biotechnology). 
Membranes were probed with anti-rabbit, anti-mouse, or anti-goat secondary antibodies 
(1:10,000 dilution, LI-COR Biosciences). Digital imaging was obtained using the Odyssey 
Infrared Imaging system (LI-COR Biosciences). Optical density (OD) of protein-of-interest 
bands were quantitated and normalized to β-actin using ImageJ software (NIH, U.S.A.).
ROS measurement
Tissue homogenates or cell lysates were prepared for ROS measurement for assessment of 
O2•− production by the cytochrome c reduction assay or detection of 2-hydroxyethidium (2-
OH-E+) peaks by HPLC, and H2O2 production by the Amplex Red assay [26,27,29–31]. 
Cytochrome c reduction assay was conducted as described previously [26]. Briefly, HPAEC 
were washed twice with ice-cold PBS and 400 µl of ice-cold disruption buffer (8 mmol/l 
potassium sodium phosphate buffer, pH 7.0, 131 mmol/l NaCl, 340 mmol/l sucrose, 2 
mmol/l NaN3, 5 mmol/lMgCl2, 1 mmol/l EGTA, 1 mmol/l EDTA, and protease inhibitor 
cocktail) was added. Cells were then scraped and subjected to five freeze/thaw cycles 
followed by five passages through a 30-gauge needle to lyse them. Lysates were centrifuged 
at 1000×g for 10 min at 4°C and the supernatant collected, and further centrifuged at 
28000×g for 20 min at 4°C to collect the membrane fraction pellet, which was resuspended 
in 100 µl disruption buffer. Total homogenates (5 µg/well) or membrane fractions (5–10 µg/
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well) were added to cytochrome c-containing oxidase assay buffer (65 mmol/l sodium 
phosphate buffer, pH 7.0, 1 mmol/l EGTA, 10 µmol/l FAD, 1 mmol/l MgCl2, 2 mmol/l 
NaN3, 0.2 mmol/l cytochrome c and 1000 U/ml catalase) and O2•− was measured as the 
initial rate of SOD (150 U/ml)-inhibitable cytochrome c reduction quantitated at 550 nm 
using the extinction coefficient 21.1 mmol−1•l cm−1 on a Biotek Synergy 4 Hybrid Multi-
Mode Microplate Reader. After a 5-min baseline measurement, NADPH (180 µmol/l) was 
added and O2•− production was calculated from the initial linear rate (first 10 min) of 
cytochrome c reduction. H2O2 production by Amplex Red assay was measured in tissue 
homogenates as described previously [27]. Briefly, frozen human lung samples were 
homogenized in HBSS-containing protease inhibitors cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany), Phospho-Stop cocktail (Roche Diagnostics GmbH, Mannheim, 
Germany), and 0.1 mM PMSF. The homogenates were centrifuged at 1000×g for 10 min at 
4°C in order to sediment undisrupted tissue, and an appropriate amount of supernatant 
(equivalent to 10 µg of protein) was loaded into black 96-well plates in assay buffer (25 mM 
Hepes, pH 7.4 containing 0.12 M NaCl, 3 mM KCl, 1 mM MgCl2, 0.1 mM Amplex Red, 
and 0.32 U/ml HRP) in the presence or absence of catalase 3000 U/ml, DPI 20 µM, or SOD 
200 U/ml. The reaction was initiated by the addition of 36 µM NADPH. Fluorescence was 
measured using a Biotek Synergy 4 Hybrid Multi-Mode Microplate Reader with a 530/25-
excitation and a 590/35-emission filter, for 30 min at 25°C. The catalase-inhibitable rate of 
H2O2 production was quantitated from an H2O2 standard curve. Intracellular O2•− detection 
by DHE-HPLC in intact HPAEC was measured as described previously [30]. Briefly, 
HPAEC were pre-incubated with DHE (10 µM) for 30 min prior to ice-cold PBS wash, 
collection, and lysis using 0.1% Triton X buffer. Cells were passed through a 30-gauge 
needle to ensure lysis, and centrifuged at 1000×g for 5 min at 4°C to remove unbroken cells. 
Proteins were precipitated out using methanol and lysates were run on a HPLC system 
equipped with a fluorescence detector to monitor the specific 2-OH-E+ O2•− peak, as 
published previously [30]. Results were normalized to protein concentrations and O2•− using 
a 2-OH-E+ standard curve.
Cell proliferation assay
Proliferation of HPAEC was measured by the CFSE CellTrace™ Cell Proliferation Kit using 
FACS, by BrdU incorporation using ELISA method or by the CyQuant® assay. CFSE FACS 
assay was conducted as described previously [28]. Briefly, HPAEC seeded into six-well 
tissue culture dishes were transfected with Grem1 siRNA or scrambled, and serum deprived 
(0.2% FBS) for 24 h. After the requisite time, cells were incubated with 1.25 µM CFSE for 
15 min. Cells were then washed with PBS and incubated under normoxic or hypoxic 
conditions for 24 h. Cells incubated for 24 h in the presence of complete growth medium 
were used as positive controls. CFSE fluorescence was evaluated by flow cytometry analysis 
using a BD LSRFortessa™ cell analyzer and data were analyzed using FlowJo (version 10). 
For BrdU incorporation, HPAEC transfected with Nox1 siRNA or scrambled were labeled 
with 10 µM BrdU (Sigma) and exposed to 21% or 1%O2 for 24 h. Twenty nanograms of 
protein was loaded onto a 96-well plate in binding buffer and incubated overnight at 4°C. 
The amount of BrdU incorporation was measured by direct ELISA using anti-BrdU 
antibody (Abcam), and developed using ABTS substrate (Pierce Bio.). The reaction product 
was quantitated by measuring the absorbance at 405 nm with a reference wavelength of 650 
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nm. Data are presented as a fold change from normoxic controls. For CyQuant assay, 
HPAEC transfected with scrambled or SHH siRNA were exposed to hypoxia or normoxia 
for 24 h and assayed for proliferation by measuring fluorescence at 520 nm using 
CyQUANT® GR dye (Thermo Fisher Scientific) as per the manufacturer’s protocol.
Confocal imaging
HPAEC cultured on 1% gelatin-coated chamber slides were fixed in 2% paraformaldehyde 
and permeabilized with 0.25% Triton X-100. After extensive washing, slides were blocked 
with 2% BSA solution followed by incubation with anti-Nox1, anti-NoxO1 or -p47phox 
antibody (1:200) and subsequent incubation with FITC- or Cy3–conjugated secondary 
antibody (1:500), respectively (Life Technologies). Slides were adhered to glass coverslips 
using gelvatol mounting medium (polyvinylalcohol, glycerol, H2O, sodium azide, and Tris; 
pH 8.5). Nonspecific rabbit or goat IgG (5 µg/ml) was used instead of primary antibody as a 
negative control. Confocal images were captured on an Olympus Fluoview 1000 confocal 
microscope (Olympus America Inc., Bethlehem, PA). For each experiment, 5–8 images per 
treatment group were captured. Three independent experiments were performed.
For immunofluorescent labeling of lung sections, 5-µm sections of antigen-retrieved, 
paraffin-embedded lungs were first washed using PBS and blocked in 10% BSA/PBS 
solution for 30 min at room temperature following permeablization. To detect specific 
antigens, the staining procedure was performed as described for cells.
Proximity ligation assay
Proximity ligation assay (PLA) assay was performed as described [32]. Duolink® II 
fluorescence assay kit (Olink Bioscience) was used according to the manufacturer’s 
instructions. Briefly, HPAEC were seeded on 1% gelatin-coated coverslips and exposed to 1 
or 21% O2 for 24 h. Cells were fixed, permeabilized, blocked, and incubated with goat anti-
Nox1 (1:500) and rabbit anti-NoxO1 (1:500) or rabbit anti-p47phox (1:500) antibody 
overnight at 4°C. The following day, secondary antibodies conjugated with oligonucleotide 
PLA probes were added, ligated, and rolling-circle amplification with fluorescent 
oligonucleotides identified positive interaction sites as recently described [33]. Cells were 
counterstained with DAPI. All images were visualized and captured using an Olympus 
Fluoview 1000 laser scanning confocal microscope. For PLA quantitation, positive 
interactions indicated by green punctates in the cytoplasm were quantitated using ImageJ 
software (NIH, U.S.A.).
Statistics
Results are expressed as mean ± S.E.M. To compare the experimental groups, Student’s t 
test or one-way ANOVA followed by Bonferroni’s correction was performed using 
GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, U.S.A.). Differences 
with P<0.05 were deemed statistically significant.
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Nox1 and Grem1 expression and ROS levels are up-regulated in PAH patient lungs
In silico analysis suggested possible common partners between Grem1 andNox1. 
Importantly, two of the genes (gene products) that were identified as putative intermediaries 
betweem Grem1 and Nox1 also associated with pulmonary hypertension. These were tumor 
necrosis factor (TNF) and kinase-insert domain receptor (KDR; Supplementary Figure S1). 
Thus, the interactome provided promise for a potential mechanistic link amongst Nox1, 
Grem1, and PAH. To investigate relevance to human diseases, we explored differences in 
Grem1 and Nox1 expression as well as ROS in lung tissue samples from PAH and non-PAH 
subjects. PAH patients had mean pulmonary artery pressures (mPAP) >25 mmHg and 
transpulmonary pressure gradient (TPG) >12 mmHg (Table 1). Figure 1A shows that both 
Nox1 and Grem1 mRNA are significantly increased in PAH lung samples compared with 
non-PAH controls (3.0 ± 1.5-fold for Nox1; 6.0 ± 1.6-fold for Grem1). These mRNA 
increases paralleled augmentation in Nox1 and Grem1 protein (Figure 1B; 1.8 ± 0.27- and 
2.0 ± 0.4-fold compared with non-PAH for Nox1 and Grem1, respectively). To localize 
Nox1 and Grem1, immunofluorescence was used. The intimal endothelial layer of lung 
blood vessels was demarcated as the region delimited circumferentially by α-smooth muscle 
actin staining, which stains the medial smooth muscle layer of blood vessels. This staining 
method was preferential as it allowed accurate identification of blood vessels and blood 
vessel remodeling. Figure 1C,D show increased intimal Nox1 and Grem1, respectively, in 
pulmonary resistance arteries (~50 µm diameter) in PAH patient lungs. We next measured 
ROS in PAH compared with non-PAH lung samples. Superoxide anion (O2•−) is rapidly 
converted into the more stable hydrogen peroxide (H2O2) [26,34]. Therefore, we employed 
the Amplex Red assay as a means of detecting comprehensive tissue ROS levels by way of 
H2O2. Consistent with the source being Nox, the assay was performed in the presence or 
absence of nonspecific flavoprotein inhibitor, DPI, and addition to lung tissue homogenates 
of NADPH as the substrate of Nox enzymatic activity [29]. As shown in Figure 1E, a 
significant increase in DPI-inhibitable H2O2 was observed in PAH patient samples compared 
with controls (0.69 ± 0.06 compared with 0.43 ± 0.032 nmol/min/mg protein, respectively). 
To corroborate this, the cytochrome c assay was employed to assess O2•− in the rat Sugen-
hypoxia (SuHx) model of occlusive, angioproliferative severe PAH, induced in female rats 
by a bolus injection of SU5416 (100 mg) followed by exposure to hypoxia (SuHx) [20–22]. 
Figure 1F shows that SuHx rat lungs display a significantly higher rate of O2•− production 
compared with normoxic controls (1.70 ± 0.07 compared with 1.33 ± 0.07 nmol/min/mg 
protein, respectively).
Nox1 subunit expression and assembly are increased in pulmonary ECs subjected to 
hypoxia
Prior studies associated Nox1 with systemic vascular reactivity, remodeling, and cell 
proliferation [11,33,35]. Evidence of Nox1 in the pulmonary circulation is however 
nonexistent. To delve into the connection between Nox1 and ROS and investigate the 
mechanism by which Nox1-derived ROS contribute to endothelial phenotypic switching in 
PAH, we utilized HPAEC subjected to hypoxia as an in vitro model resembling this disease. 
mRNA levels of canonical or hybrid Nox1 oxidase components (Nox1, NoxO1, p47phox, and 
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NoxA1) were monitored following 6, 12, 24, 36, and 48 h hypoxia (1% O2). Nox1 mRNA 
increased in response to 24 h hypoxia (3.0 ± 0.51-fold compared with normoxic control; 
Figure 2A and Supplementary Figure S2). Canonical Nox1 organizer subunit NoxO1 mRNA 
levels exhibited a trend toward an increase at 24 h (1.6 ± 0.27-fold, P=0.051; Figure 2A and 
Supplementary Figure S2). In contrast, there were no observed differences in Nox1 activator 
subunit NoxA1 or hybrid Nox1 organizer subunit p47phox mRNA (which supplants NoxA1 
in the Nox1 hybrid system). The increase in Nox1 mRNA at 24 h correlated with an increase 
in Nox1 protein in response to hypoxia (Figure 2B; 1.6 ± 0.10-fold compared with 
normoxia). There was also a small but significant increase in NoxO1 protein (Figure 2C). 
Since the canonical Nox1 system is considered to be constitutively active (whereby its 
activity is transcriptionally regulated) whereas the hybrid system employing p47phox can be 
activated via post-translational modifications [26,33,34], it was crucial to explore which 
system predominates in propagating hypoxia-induced endothelial ROS. We, therefore, 
examined Nox1 oxidase assembly by testing colocalization of Nox1 with either NoxO1 or 
p47phox in HPAEC subjected to hypoxia (24 h). Nox1 and NoxO1 expression were increased 
by hypoxia (Figure 2D), consistent with Western blot data. Importantly, Nox1 and NoxO1 
colocalization increased in response to hypoxia both in the cytosol and plasma membrane 
(Figure 2D), consistent with Nox1 oxidase’s established presence in endosomes and 
caveolae [34,36]. Moreover, while confocal data suggest an increase in p47phox in response 
to hypoxia, colocalization of Nox1 and p47phox appeared weaker than that of Nox1–NoxO1 
(Figure 2E).
Given these data, we tested whether the Nox1 system is the only Nox oxidase isoform up-
regulated in ECs in response to hypoxia. Nox2 andNox4 have been implicated in PAH 
[10,37–39]. We, therefore, examined the expression ofNox2 andNox4 in HPAEC subjected 
to 24 h hypoxia, and in contrast with Nox1, there were no observed differences in the 
expression of either Nox2 or Nox4 (Supplementary Figure S3).
Since colocalization is consistent with, but does not confirm, association, we employed PLA 
to evaluate Nox1 oxidase subunit interaction. Figure 3 reveals that NoxO1 and p47phox 
indeed both interact with Nox1, supporting assembly of both the canonical and hybrid 
oxidase systems under hypoxia, respectively. There is increased interaction in Nox1 and 
NoxO1 throughout the cytosol (Figure 3A) supporting previously reported Nox1’s presence 
in endosomes [36]. Likewise, Nox1-p47phox is also present, to a lesser extent, with the same 
localization (Figure 3B). Thus, the canonical system appears to predominate as the major 
assembled Nox1 oxidase in hypoxic HPAEC (Figure 3C).
Hypoxia induces Nox1-derived ROS
To test whether the increase in Nox1 oxidase expression and assembly results in increased 
ROS, HPAEC subjected to hypoxia (1% O2, 24 h) were assessed for O2•− production by the 
cytochrome c assay. Figure 4A,B show a significant O2•− increase compared with normoxia 
(14.0 ± 1.9 compared with 6.00 ± 0.94 nmol/min/mg protein). To confirm this increase, 
DHE oxidation (into 2-OH-E+, an indicator of intracellular O2•−) using HPLC, was 
monitored [30]. Figure 4C,D show that hypoxia induced intracellular O2•− compared with 
normoxia (33 ± 5 compared with 21 ± 3 nM, respectively). To verify whether this increase in 
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O2•− was Nox1-derived, HPAEC were transfected with scrambled (Scr) or Nox1 siRNA for 
24 h prior to hypoxia treatment and evaluated for O2•−. Nox1 siRNA reduced Nox1 protein 
expression by over 60% (Figure 4E). Figure 4F demonstrates that Nox1 gene-silencing 
reduced hypoxia-induced O2•− production by a similar extent (31.7 ± 2.5 compared with 
19.4 ± 1.6 nmol/min/mg protein for Scr compared with Nox1 siRNA hypoxia groups, 
respectively).
Hypoxia induces Nox1-mediated Grem1 and SHH expression
To interrogate a link between Nox1-derived ROS and Grem1, we first tested whether Grem1 
expression is up-regulated in pulmonary ECs. HPAEC were subjected to hypoxia and Grem1 
mRNA and protein were quantitated. Figure 5A shows that Grem1 mRNA is significantly 
up-regulated by hypoxia (3.0 ± 0.024-fold compared with normoxia). This was accompanied 
by a significant increase in Grem1 protein by both Western blot (1.90 ± 0.32-fold relative 
compared with normoxia; Figure 5B) and confocal microscopy (Supplementary Figure S4). 
This up-regulation coincides with the time dependence of Nox1 expression, assembly, and 
ROS production in response to hypoxia. Thus, we tested a causal link by investigating 
whether the increase in Grem1 expression is Nox1 dependent. HPAEC were transfected with 
Nox1 or Scr siRNA and evaluated for Grem1 protein. Figure 5C shows that Nox1 
knockdown abolished hypoxia-induced Grem1, revealing for the first time that hypoxia-
induced Nox1 activation up-regulates Grem1 expression in pulmonary ECs.
To gain greater insight into the effector of Nox1-derived ROS on Grem1 expression, we 
investigated a possible involvement of SHH. We focussed on this pathway as it is a key 
driver of cellular pattern formation, differentiation, and proliferation [19,40], and has been 
implicated in arterial remodeling [41]. First, we explored whether SHH is differentially 
expressed in lung tissue samples from PAH and non-PAH subjects. Western blot data 
(Supplementary Figure S5) show that SHH is increased in PAH lung samples compared with 
non-PAH controls (2.5 ± 0.7-fold). Despite being very close, these data, however, did not 
reach statistical significance, likely owing to human tissue variability (P=0.0515). HPAEC 
were transfected with Nox1 or scrambled siRNA and subjected to hypoxia (24 h). Figure 5D 
shows that hypoxia induced SHH expression (1.5 ± 0.011-fold compared with normoxic 
control). Importantly, Nox1 gene-silencing abolished this increase (Figure 5D), supporting 
aNox1-dependent activation of SHH signaling, an upstream modulator of Grem1 [42–44]. 
To further support that Nox1-derived ROS activates SHH, we treated HPAEC exogenously 
with varying concentrations of H2O2. H2O2 treatment (100 µM, 4 h) resulted in a significant 
increase in SHH expression (Supplementary Figure S6). Finally, to test whether SHH is 
causally linked to Grem1 expression and pulmonary EC proliferation, SHH siRNA was 
transfected into HPAEC and subjected to normoxia or hypoxia. Supplementary Figure S7 
shows that SHH siRNA abolished hypoxia-induced Grem1 expression and HPAEC 
proliferation, supporting activation of a Nox1-SHH-Grem1 pro-proliferative pathway under 
endothelial hypoxic stress.
Hypoxia elicits pulmonary EC proliferation in Nox1- and Grem1-dependent manner
Grem1 is a BMP receptor antagonist that can act in an autocrine fashion to inhibit BMP 
signaling, leading to proliferation [12,13,15,16,45]. To investigate whether the increase in 
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Nox1 and attendant increase in Grem1 results in a proliferative response, HPAEC were 
transfected with Nox1 or scrambled siRNA, subjected to 24 h hypoxia and cellular 
proliferation assessed by BrdU incorporation [46]. A significant increase in HPAEC BrdU 
incorporation was found following hypoxia (1.18 ± 0.038-fold relative to normoxic control), 
a response that was abolished by Nox1 siRNA (Figure 6A). To test the putative role of 
Grem1, hypoxia-induced HPAEC proliferation was quantitated using CFSE fluorescence by 
FACS after transfection with Grem1 or scrambled siRNA. Figure 6B shows that hypoxia 
induced a significant increase in the number of proliferating cells compared with normoxia 
(4.6 ± 1.4% compared with 1.0% of total cells, respectively). Importantly, gene silencing of 
Grem1 abolished hypoxia-induced proliferation (Figure 6B,C).
Discussion
The mechanisms responsible for pulmonary vascular endothelial proliferation in PAH 
remain poorly understood. The major findings of the current study culminate in the 
discovery of a Nox1-instigated cellular process that drives proliferation via SHH and Grem1 
in the pulmonary endothelium. This pathway was activated in lungs from PAH patients, 
supporting its clinical significance. The oxidase capacity of Nox1 in the PAH endothelium is 
activated through assembly of both the canonical and hybrid Nox1 systems. These elicit an 
increase in Nox1-derived ROS and subsequent up-regulation of SHH and Grem1 expression, 
as revealed by changes in protein expression. Grem1 release ensues and leads to an increase 
in pulmonary endothelial proliferation (Figure 7).
Our data on Nox1 expression and assembly reveal critical new information on how this 
enzyme functions in the pulmonary endothelium and, to our knowledge, ECs in general. 
Multiple lines of evidence support an increase in Nox1 and, to a lesser extent NoxO1, 
expression in PAH. We show by qPCR, Western blotting, and confocal microscopy an 
increase in Nox1 expression both in PAH patients’ lungs and isolated HPAEC subjected to 
hypoxia. We also show by confocal imaging and the PLA assay increased assembly of the 
canonical (involving NoxO1) and hybrid (involving p47phox) Nox1 systems in hypoxic ECs. 
Activation of NoxO1 is thought to be regulated through expression and NoxO1 participation 
in Nox1 oxidase activity occurs via a constitutive association with Nox1 yielding a 
constitutively assembled and active Nox1 oxidase system [34]. This is in contrast with 
p47phox, which is widely accepted to be activated upon phosphorylation, causing 
conformational changes that expose Nox-binding domains [33,34]. The observation that 
both canonical and hybrid Nox1 systems are activated in EC under the same stimulus 
(hypoxia in the current study) suggest a dual mode of Nox1 activation during PAH. Since 
p47phox phosphorylation is necessary for its membrane translocation and association with 
catalytic subunits, one mode of Nox1 oxidase activation in these cells could be an acute 
response that involves increased assembly and activation of pre-existent subunits of the 
enzyme. The other mode could be a more chronic adaptation and involve increased 
expression of Nox1 and NoxO1. Further experimentation would be necessary, however, to 
support this notion of an acute compared with chronic response during PAH and to test 
whether these responses could underlie events of PAH initiation and prolongation, 
respectively. The observed increase in ROS in human PAH lungs, rat SuHx lungs, and 
cultured ECs exposed to hypoxia (confirmed by three independent and robust detection 
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methods) and attenuation of this increase by Nox1 gene silencing further support Nox1’s 
role in PAH.
Despite the fact that EC proliferation is crucial for initiation and progression of severe 
pulmonary hypertension [47], the mechanisms driving this process are not well understood. 
Our data demonstrate that Grem1 mRNA and protein are increased in PAH patient lungs as 
well as in hypoxic HPAEC. We also demonstrate that loss of Grem1 attenuates hypoxia-
induced EC proliferation. These data are consistent with the previous findings of a role 
forGrem1 in vascular remodeling in PAH [14,16–18,45]. Importantly, we expand 
significantly on previous discoveries by demonstrating a heretofore unknown Nox1-
dependent regulation of Grem1. Our findings demonstrate that Nox1 gene silencing 
attenuates hypoxia-induced Grem1 protein expression and EC proliferation and support a 
Nox1–Grem1 causal relationship that contributes to the PAH vascular phenotype. Further 
insight into this signaling pathway is gained by data demonstrating for the first time that 
Nox1 gene-silencing attenuates hypoxia-induced SHH expression. These findings built upon 
previous reports supporting that SHH is up-regulated in response to oxidative stress [48,49] 
and associated with cell proliferation and arterial remodeling [40,41]. Previous studies have 
also demonstrated that Grem1 is downstream of SHH signaling [42–44]. Indeed, our current 
data demonstrated that in ECs, SHH is up-regulated in response to Nox1 oxidase activation 
and in response to exogenous H2O2; and support up-regulation of SHH in PAH patients. We 
also showed that SHH is upstream of Grem1 expression and pulmonary EC proliferation 
following hypoxic insult. In aggregate, our findings support a mechanism whereby SHH is 
an intermediary between hypoxia-induced Nox1-derived ROS and Grem1 and, in turn, 
endothelial proliferation.
Definitive identification ofNox1’s role as an upstream modulator ofGrem1 in the pulmonary 
endothelium appears to quell some of the controversy confounding a role for various Nox 
isoforms in PAH-associated vascular remodeling [50–54]. Careful consideration of this 
literature reveals that Nox isoforms in PAH are likely to play cell-specific roles in the 
disease. Our current data unveil a unique role for Nox1 in endothelial proliferation in PAH. 
Therapeutic implications of the Nox1–Grem1 pathway are brought to the forefront by our 
human tissue and rat PAH data.
Taken together, the findings of the current study identify a novel signaling axis in PAH in 
which pulmonary vascular endothelial Nox1 is activated, leading to an increase in ROS, 
SHH, and a subsequent increase in Grem1 expression. The rise in Grem1 drives an increase 
in endothelial proliferation that contributes to the pathogenesis of PAH. These findings were 
supported by data collected from human tissues, underscoring clinical relevance of this new 
signaling pathway, and identifying the Nox1–Grem1 axis as a potential new target for 
multipronged therapeutic strategies.
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• PAH is a rapidly degenerating disease that leads to death from right heart 
failure. Despite the availability of a number of FDA-approved drugs, 
prognosis remains poor, largely attributed to limited understanding of 
mechanisms driving the underlying vascular remodeling. While endothelial 
proliferation is considered by many to propagate pathological remodeling of 
the pulmonary vasculature, little is known about how the pulmonary 
endothelium is regulated in PAH.
• Our current findings demonstrate up-regulation of Nox1, Grem1, and ROS in 
human PAH lungs and hypoxia-exposed human pulmonary ECs. We report a 
novel signaling pathway whereby Nox1 drives SHH and Grem1 induction and 
leads to pulmonary EC proliferation.
• This new signaling axis has broad implications on the angioproliferative and 
vasculo-occlusive processes driving PAH in patients and may serve as a 
promising therapeutic target for future development of new classes of anti-
PAH drug.
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Figure 1. Human PAH is associated with increased Nox1 and Grem1 expression and elevated 
ROS production that is paralleled in rat PAH
(A) Real-time qPCR analysis of Nox1 and Grem1 mRNA levels normalized to 18S in lung 
tissue samples from patients with PAH compared with non-PAH controls (n=3–5). (B) 
Western blot analysis of Nox1, Grem1, and β-actin protein levels in lung tissue samples 
from patients with PAH compared with non-PAH controls. Bar graph shows densitometry 
quantitation of protein expression normalized to β-actin protein expression (n=7–9). (C,D) 
Expression of Nox1 (C, red) and Grem1 (D, red) in PAH and non-PAH human lung sections 
by co-immunofluorescent staining. Sections were counterstained with α-smooth muscle 
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actin (green) to visualize the medial smooth muscle layer of blood vessels, and DAPI (blue) 
to visualize the nuclei; the endothelial layer (intima) was defined as the layer delimited 
circumferentially by α-smooth muscle actin staining; L refers to vessel lumen. Scale bars 
represent 50 µm. (E) Increased DPI-inhibitable total homogenate comprehensive tissue ROS 
levels (direct H2O2 production plus dismuted O2•−) in lungs of PAH patients compared with 
non-PAH controls as measured by Amplex Red fluorescence for evaluation of H2O2 (n=4). 
*P<0.05 compared with non-PAH by Student’s t test. (F) Increased O2•− in total lung 
homogenates of SuHx-treated rats compared with normoxia-treated controls measured by 
the cytochrome c reduction assay. **P<0.01 compared with normoxia (n=5). The results are 
means ± S.E.M. of indicated sample size.
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Figure 2. Hypoxia increases expression of Nox1 oxidase and its subunits in HPAEC
(A) Analysis by qPCR of Nox1, NoxA1, NoxO1, and p47phox mRNA levels normalized to 
18S in HPAEC in response to 24 h of hypoxia depicted as fold from normoxic control (n=3–
6). (B,C) Western blot analysis of Nox1 and NoxO1 protein levels in response to 24 h of 
hypoxia in HPAEC; bar graphs depict densitometry quantitation normalized to β-actin (n=6–
8). *P<0.05; **P<0.01; ***P<0.001 compared with normoxia by Student’s t test. (D,E) 
Confocal immunofluorescence images of Nox1 showing increased expression and 
colocalization with NoxO1 and p47phox following 24 h hypoxia in HPAEC. HPAEC were 
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double immunostained for NoxO1 (green, D) or p47phox (green, E), and Nox1 (red, D and 
E). Inset shows magnification of areas of colocalization; n=3.
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Figure 3. Hypoxia increases binding of Nox1 oxidase subunits in HPAEC
(A,B) PLA for Nox1 and p47phox or Nox1 and NoxO1 (green punctates) following 24 h 
hypoxia in HPAEC. Nuclei were stained with DAPI (blue). (C) Quantitation of PLA results 
from A and B (n=3). *P<0.05; ***P<0.001 compared with normoxia; #P<0.05 compared 
with Nox1–NoxO1 interaction in hypoxia.
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Figure 4. Hypoxia induces ROS in HPAEC, which is attenuated by Nox1 silencing
(A) Membrane fractions were prepared from HPAEC exposed to normoxia or hypoxia for 
the indicated times and assayed for O2•− levels by cytochrome c reduction assay (n=6); 
**P<0.01 compared with normoxia. (B) Representative cytochrome c absorbance over time 
plots. (C) HPAEC were exposed to hypoxia for 24 h and pretreated for 30 min with 10 µM 
DHE prior to lysis. Evaluation of O2•− levels was made using DHE-HPLC assay (n=5); 
*P<0.05 compared with normoxia. (D) Representative HPLC retention time plot. Values on 
plot indicate retention times and concentrations of 2-OH-E+ for one representative plot 
(E)Western blot analysis of Nox1 in HPAEC following transfection with scrambled (Scr) or 
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Nox1 siRNA (n=3); **P<0.01 compared with Scr. (F) HPAEC transfected with scrambled 
(Scr) or Nox1 siRNA were exposed to hypoxia for 24 h, and then assayed for O2•− levels by 
cytochrome c reduction assay using membrane fractions (n=9); ***P<0.001 compared with 
Scr normoxia, #P<0.05 compared with Scr hypoxia by one-way ANOVA.
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Figure 5. Hypoxia induces Nox1-dependent Grem1 expression in HPAEC
(A) Real-time qPCR analysis of Grem1 mRNA expression normalized to 18S in HPAEC 
subjected to hypoxia for the indicated times shown as fold from respective normoxic 
controls (n=6). (B) HPAEC were exposed to hypoxia for 24 h and then lysed and subjected 
to Western blotting for Grem1 and β-actin. Bar graph shows absorbance quantitation 
normalized to β-actin and depicted as fold from normoxia (n=6). (C) HPAEC transfected 
with Nox1 siRNA or scrambled siRNA (Scr) were exposed to hypoxia for 24 h, and then 
lysed and subjected to Western blotting for Grem1 and β-actin. Bar graph shows absorbance 
quantitation normalized to β-actin and depicted as fold from Scr normoxia control (n=6). 
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(D) Western blot analysis of SHH expression in HPAEC transfected with Nox1 siRNA 
(siRNA) or scrambled control siRNA (Scr) and subjected to 24 h hypoxia; bar graph shows 
absorbance quantitation normalized to β-actin and depicted as fold from Scr normoxia 
control (n=3). ***P<0.001 compared with normoxia, **P<0.01 compared with respective 
normoxia group, #P<0.01 compared with Scr hypoxia, *P<0.05 compared with respective 
normoxia group by Student’s t test (A,B) or one-way ANOVA (C,D).
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Figure 6. Loss of Nox1 or Grem1 attenuates hypoxia-induced HPAEC proliferation
HPAEC were transfected with Scr, Nox1 or Grem1 siRNA and exposed to hypoxia for 24 h. 
(A) HPAEC proliferation was assessed by BrdU incorporation following transfection of cells 
with Nox1 or Scr siRNA and subjecting them to 24 h hypoxia. Data are shown as means ± 
S.E.M. of fold change relative to Scr normoxia control (n=6). (B) Proliferation of HPAEC 
following transfection with Grem1 or Scr siRNA and 24 h hypoxia treatment was assessed 
by the CFSE FACS assay. Data are shown as percent proliferating cells. (C) Representative 
CFSE FACS tracings wherein the red spectrum indicates CFSE intensity in proliferating 
cells and gray spectrum indicates non-proliferating controls (n=3). *P<0.05 compared with 
Scr normoxia, #P<0.05 compared with Scr hypoxia.
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Figure 7. Schematic diagram showing Nox1-Grem1 activation pathway in EC proliferation and 
RV hypertrophy
Hypoxia exposure of pulmonary ECs leads to Nox1-derived ROS production, which in turn 
activates SHH leading to Grem1 expression. This increase in Grem1 expression results in an 
unregulated proliferative process that ultimately leads to PAH and RV hypertrophy.
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